Atlanta Consulting Group Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Atlanta Consulting Group Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-500	Closed	-$242K	–	133
2025 Q1	$242K	Buy	+500	New	+$233K	0.07%	107
2024 Q4	–	Sell	-1,769	Closed	-$823K	–	225
2024 Q3	$823K	Buy	1,769 +1,331	+304%	+$639K	0.2%	96
2024 Q2	$205K	Buy	+438	New	+$190K	0.04%	112

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Atlanta Consulting Group Advisors's VRTX Position: Q2 2025 in Review

Atlanta Consulting Group Advisors sold out of Vertex Pharmaceuticals (VRTX) in Q2 2025, closing a stake of 500 shares — an estimated $242K sold.

Atlanta Consulting Group Advisors first reported a position in VRTX in Q2 2024 and held it in 3 quarters. The position peaked at $823K in Q3 2024. 1,559 funds tracked by Wall St. Rank hold VRTX as of Q2 2025.

Atlanta Consulting Group Advisors reported no remaining Vertex Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
Atlanta Consulting Group Advisors sold 500 Vertex Pharmaceuticals shares in Q2 2025, an estimated $242K.
Atlanta Consulting Group Advisors first reported a position in Vertex Pharmaceuticals in Q2 2024 and held it in 3 quarters.
Atlanta Consulting Group Advisors's Vertex Pharmaceuticals position peaked at $823K in Q3 2024.
1,559 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2025.

Based on Atlanta Consulting Group Advisors's 13F filing for Q2 2025, filed 8 Aug 2025.